Lexicon Pharmaceuticals, Inc. (LXRX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Lexicon Pharmaceuticals (LXRX) Q1 2026: $20M Novo Nordisk Milestones Drive Cash Surge Ahead of Sonata HCM Readout
May 07, 2026
-
Lexicon Pharmaceuticals (LXRX) Q4 2025: Operating Expenses Cut $129M as Pipeline Readies for 2026 Catalysts
March 05, 2026
-
Lexicon (LXRX) Q3 2025: Licensing Revenue Jumps to $13.2M as R&D Refocus Drives Cost Reset
November 06, 2025
-
Lexicon Pharmaceuticals (LXRX) Q2 2025: $28.9M Licensing Revenue Flips Profitability as R&D Pivot Accelerates
August 06, 2025
-
Lexicon Pharmaceuticals (LXRX) Q1 2025: Novo Nordisk Deal Secures $45M Upfront, Reshapes R&D Trajectory
July 07, 2025